-
Featured Authors
Patently BIOtech
Archive
- May 2013 (2)
- April 2013 (5)
- March 2013 (2)
- February 2013 (4)
- January 2013 (1)
- December 2012 (2)
- November 2012 (3)
- October 2012 (3)
- September 2012 (3)
- August 2012 (5)
- July 2012 (4)
- June 2012 (7)
- May 2012 (5)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
The Critical Importance of International Patent Protection for Small Businesses
As part of the implementation of the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office (PTO) recently held two public hearing on international patent protection. Stanley C. Erck, President and CEO of Novavax, Inc., testified on behalf of BIO in support of an initiative to reduce filing and prosecution costs for international patent protection of biotech inventions. In his testimony, Mr. Erck explained the important role patents play in the biotechnology industry. The Read More >
Commercialization and Job Creation in the Biotechnology Sector
It’s tough presenting programs on technology transfer because so much has already been said that it’s hard to find something new. However, that was not a problem this week in San Francisco at the BIO Technology Transfer Symposium. The Symposium began with an overview of the efforts by the Obama Administration to spur innovation including funding macro and micro grants to encourage the development of regional technology clusters, and proof of concept centers to help Read More >
EU Stem Cell Patent Decision Hurts Science
A great article in the Economist titled European science stemmed addresses the recent and controversial decision by the European Court of Justice regarding the patentability of certain inventions derived from embryonic stem cells. ANY country, you might think, would relish being able to call itself the world’s leader in scientific research. America and Europe, however, seem to be in a bizarre parallel contest: which can make its scientists’ lives more difficult by imposing the most muddled Read More >
KORUS and BIO’s New Senior Vice President for International Affairs
Earlier this week, Joseph Damond joined BIO as Senior Vice President of International Affairs. He brings extensive experience in international affairs, trade and economics, most recently serving as Vice President of International Government Relations at Pfizer, Inc. He previously served as Deputy Vice President for International Affairs at PhRMA and as the Deputy Assistant for the Asia-Pacific region in the Office of the U.S. Trade Representative. Joe will spearhead BIO’s international trade policy and help Read More >
Australian Senate Committee Recommends Against Banning ‘Gene Patents’
The Australian Senate Legal and Constitutional Affairs Legislation Committee recommended against the Patent Amendment (Human Genes and Biological Materials) which would have banned DNA patents in Australia. The push by members of the Australian Senate seemed to mirror efforts in the United States surrounding the Myriad case. The Committee found that: “While previous inquiries and public discussions have focused on the patenting of human genes, the Bill goes further and proposes a specific exclusion for biological materials which Read More >
